Pharmacovigilance-an Emergence

Download Article

Authors : Deven V Parmar, Dharani Munirathinam


Pharmacovigilance (PV), defined by the world health organization (WHO) as the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem. Emergence of PV activities and the awareness would play a vital role in ensuring that doctors, healthcare professional, together with the patient, have enough information to make an educated decision when it comes to choosing a drug for treatment and eventually achieving the patient safety in large. 


[1.] Adis International. The Erice Manifesto: for global reform of the safety of medicines in patient care. Drug Saf 2007; 30:187-90.

[2.] Assessment of the European Community System of Pharmacovigilance. European Medicines Agency 2006. Available via Accessed March 1, 2012.

[3.] Biswas P, Biswas AK. Setting standards for proactive pharmacovigilance in India. Indian J Pharmacol. 2007;39:124–8.

[4.] Chapter 6 of The SAFETY of MEDICINES IN PUBLIC HEALTH PROGRAMMES: Pharmacovigilance an essential tool. WHO book.

[5.] Coombes R. FDA tightens its grip on drug regulation. BMJ 2007; 334:290-1.

[6.] Directive 2010/84/EU. Official Journal of the European Union 2010, Dec 31,L. 348/74-99.

[7.] European Medicine Agency Updates on RMP: EMA website ing_000360.jsp

[8.] European Risk management Strategy: Achievements to date. European Medicines Agency 2007. Available via Accessed Dec 18 2007.

[9.] Good Pharmacovigilance Practices. European medicines Agency 2012. Available via http:// 00345.jsp&mid=#section1 Accessed March 1, 2012.

[10.]   Heath G, Colburn WA. An evolution of drug development and clinical pharmacology during the 20th century. J ClinPharmacol 2000; 40:918-29.

[11.]   Hugman B. The Ericedeclaration : the critical role of communication in drug safety. Drug Saf 2006; 29:91-3.

[12.]   McBride WG. Thalidomide and congenital malformations. Lancet 1961; 2:1358.

[13.]   McClellan M. Drug safety reform at the FDA-pendulum swing or systematic improvement? N EnglJ Med 2007; 356:1700-2.

[14.]   Merck Announces Voluntary Worldwide Withdrawal of VIOXX. Merck & Co. 2004. Available via Accessed March 1, 2012.

[15.]   Nair MD. Pharmacovigilance: the need for a formal system in India. 2001. Available at the site of Pharmabiz = 11329&sectionid = 46 .

[16.]   Protocol for National Pharmacovigilance Program. 2004 Nov; CDSCO, Ministry of Health and Family Welfare, Government of India.

[17.]   Raine JM. Risk management -a European Regulatory View. In: Mann R, Andrews E (eds) Pharmacovigilance.2nd edn 2007. Wiley, Chichester.

[18.]   Regulation 1235/2010. Official Journal of the European Union 2010, Dec 31,L. 348/1-16.

[19.]   REMS update and guidelines by FDA: Website

[20.]   Schedule Y. 2005 Jan; CDSCO, Ministry of Health and Family Welfare, Government of India.

[21.]   Status Report on the Implementation of the European Risk management Strategy. European Medicines Agency 2007. Available via Accessed Dec 18, 2007.

[22.]   The Importance of Pharmacovigilance. WHO 2002. Available via Accessed Jan 20, 2012.

[23.]   VanGrootheest K. The dawn of pharmacovigilance: an historical perspective. Int J Pharm Med 2003; 17:195-200.

[24.]   Waller PC, Evans SJ. A model for the future conduct of pharmacovigilance. Pharmacoepidemiol Drug Saf 2003; 12:17-29.

[25.]   Whitworth DR. India's pharmacovigilance system to monitor adverse reactions of drugs. Available at the site of Regulatory Affairs Focus Magazine = &CID = 61&DID = 26350 .

[26.]   Zwillich T. US lawmakers tackle safety reforms at the FDA. Lancet 2007; 369:1989-90.